Patents by Inventor Hanna EILKEN

Hanna EILKEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyridobenzodiazepinone-derivatives and use thereof
    Patent number: 10047096
    Abstract: The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: August 14, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas Schall, Jürgen Klar, Mario Lobell, Hartmut Schirok, Joachim Telser, Steffen Müller, Dirk Brohm, Hans Briem, Hannah Jörißen, Joerg Keldenich, Michael Böttger, Georges Von Degenfeld, Thomas Schlange, Ulf Bömer, Niels Lindner, Hanna Eilken, Dmitrij Hristodorov, Pierre Wasnaire, Kersten Matthias Gericke, Lars Bärfacker
  • SUBSTITUTED PYRIDOBENZODIAZEPINONE-DERIVATIVES AND USE THEREOF
    Publication number: 20170253602
    Abstract: The present application relates to novel (3-hydroxyphenyl)amino-substituted pyrido[2,3-b][1,5]benzodiazepin-5-one derivatives, to processes for preparation thereof, to the use thereof alone or in combination for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially of angiogenic disorders and hyperproliferative disorders in which neovascularization plays a role, for example ophthalmological disorders and cancers and tumours. Such treatments can be effected as monotherapy or else in combination with other medicaments or further therapeutic measures.
    Type: Application
    Filed: November 23, 2015
    Publication date: September 7, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas SCHALL, Jürgen KLAR, Mario LOBELL, Hartmut SCHIROK, Joachim TELSER, Steffen MÜLLER, Dirk BROHM, Hans BRIEM, Hannah JÖRIßEN, Joerg KELDENICH (deceased), Michael BÖTTGER, Georges DEGENFELD VON, Thomas SCHLANGE, Ulf BÖMER, Niels LINDNER, Hanna EILKEN, Dmitrij HRISTODOROV, Pierre WASNAIRE, Kersten Matthias GERICKE, Lars BÄRFACKER